These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 32067332

  • 1. Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients.
    Seo E, Kim J, Oh SH, Kim KM, Kim DY, Lee J.
    Pediatr Transplant; 2020 Jun; 24(4):e13666. PubMed ID: 32067332
    [Abstract] [Full Text] [Related]

  • 2. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
    Chen HS, Ho MC, Hu RH, Wu JF, Chen HL, Ni YH, Hsu HY, Jeng YM, Chang MH.
    J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
    [Abstract] [Full Text] [Related]

  • 3. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, Merli P, Barzon L, Murer L, Piga S, Ciofi Degli Atti ML, Locatelli F, Dello Strologo L.
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [Abstract] [Full Text] [Related]

  • 4. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
    Quintero Bernabeu J, Juamperez J, Mercadal-Hally M, Larrarte King M, Gallego Melcon S, Gros Subias L, Sábado Álvarez C, Soler-Palacin P, Melendo Pérez S, Esperalba J, Navarro Jiménez A, Garrido Pontnou M, Camacho Soriano J, Hidalgo Llompart E, Bilbao Aguirre I, Charco Torra R.
    Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD, Durand KA, Solernou V, Bosaleh A, Balbarrey Z, García de Dávila MT, Rodríguez M, Irazu L, Alonio LV, Picconi MA.
    Rev Argent Microbiol; 2016 Sep; 48(2):110-8. PubMed ID: 27157146
    [Abstract] [Full Text] [Related]

  • 6. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C, Giacchino F, Bergallo M, Bonello F, Bollero C, Segoloni GP, Cavallo R.
    G Ital Nefrol; 2003 Sep; 20(2):170-5. PubMed ID: 12746803
    [Abstract] [Full Text] [Related]

  • 7. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 8. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C, Cavallo R, Bergallo M, Giacchino F, Bollero C, Negro Ponzi A, Cavallo G.
    New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
    [Abstract] [Full Text] [Related]

  • 9. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients.
    Scheenstra R, Verschuuren EA, de Haan A, Slooff MJ, The TH, Bijleveld CM, Verkade HJ.
    Transpl Infect Dis; 2004 Mar; 6(1):15-22. PubMed ID: 15225222
    [Abstract] [Full Text] [Related]

  • 10. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [Abstract] [Full Text] [Related]

  • 11. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
    Baldanti F, Rognoni V, Cascina A, Oggionni T, Tinelli C, Meloni F.
    Virol J; 2011 Sep 05; 8():421. PubMed ID: 21892950
    [Abstract] [Full Text] [Related]

  • 12. Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy.
    Kullberg-Lindh C, Saalman R, Olausson M, Herlenius G, Lindh M.
    Pediatr Transplant; 2017 Aug 05; 21(5):. PubMed ID: 28039929
    [Abstract] [Full Text] [Related]

  • 13. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 05; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 14. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M.
    J Pediatr Gastroenterol Nutr; 2004 Feb 05; 38(2):198-203. PubMed ID: 14734884
    [Abstract] [Full Text] [Related]

  • 15. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 05; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 16. Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads.
    Kamei H, Ito Y, Kawada J, Ogiso S, Onishi Y, Komagome M, Kurata N, Ogura Y.
    Transpl Infect Dis; 2018 Aug 05; 20(4):e12911. PubMed ID: 29677384
    [Abstract] [Full Text] [Related]

  • 17. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients.
    Chang YC, Young RR, Mavis AM, Chambers ET, Kirmani S, Kelly MS, Kalu IC, Smith MJ, Lugo DJ.
    PLoS One; 2022 Nov 27; 17(10):e0269766. PubMed ID: 36256635
    [Abstract] [Full Text] [Related]

  • 19. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, Anand R, Yin W, Studies of Pediatric Liver Transplantation Research Group.
    Liver Transpl; 2013 Jul 27; 19(7):730-40. PubMed ID: 23696264
    [Abstract] [Full Text] [Related]

  • 20. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA.
    Clin Transplant; 2006 Jul 27; 20(3):389-93. PubMed ID: 16824159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.